These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 29253572)
61. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Belyanskaya LL; Hopkins-Donaldson S; Kurtz S; Simões-Wüst AP; Yousefi S; Simon HU; Stahel R; Zangemeister-Wittke U Int J Cancer; 2005 Dec; 117(5):755-63. PubMed ID: 15981204 [TBL] [Abstract][Full Text] [Related]
62. HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells. Zhou J; Chen X; Gilvary DL; Tejera MM; Eksioglu EA; Wei S; Djeu JY Sci Rep; 2015 Oct; 5():15085. PubMed ID: 26469759 [TBL] [Abstract][Full Text] [Related]
63. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Zoubeidi A; Chi K; Gleave M Clin Cancer Res; 2010 Feb; 16(4):1088-93. PubMed ID: 20145158 [TBL] [Abstract][Full Text] [Related]
64. Therapeutic role of meloxicam targeting secretory clusterin-mediated invasion in hepatocellular carcinoma cells. Zhong J; Yu X; Dong X; Lu H; Zhou W; Li L; Li Z; Sun P; Shi X Oncol Lett; 2018 May; 15(5):7191-7199. PubMed ID: 29731881 [TBL] [Abstract][Full Text] [Related]
65. Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma. Narahara S; Watanabe T; Nagaoka K; Fujimoto N; Furuta Y; Tanaka K; Tokunaga T; Kawasaki T; Yoshimaru Y; Setoyama H; Oniki K; Saruwatari J; Tateyama M; Naoe H; Tanaka M; Tanaka Y; Sasaki Y Hepatol Commun; 2022 May; 6(5):1198-1212. PubMed ID: 34837478 [TBL] [Abstract][Full Text] [Related]
66. Molecular basis of V-ATPase inhibition by bafilomycin A1. Wang R; Wang J; Hassan A; Lee CH; Xie XS; Li X Nat Commun; 2021 Mar; 12(1):1782. PubMed ID: 33741963 [TBL] [Abstract][Full Text] [Related]
67. Biosynthetic investigations of the V-type ATPase inhibitors bafilomycin A1, B1 and concanamycin A. Schuhmann T; Grond S J Antibiot (Tokyo); 2004 Oct; 57(10):655-61. PubMed ID: 15638326 [TBL] [Abstract][Full Text] [Related]
68. Survivin degradation by bergenin overcomes pemetrexed resistance. Li X; Liang Q; Zhou L; Deng G; Xiao Y; Gan Y; Han S; Liao J; Wang R; Qing X; Li W Cell Oncol (Dordr); 2023 Dec; 46(6):1837-1853. PubMed ID: 37542022 [TBL] [Abstract][Full Text] [Related]
69. Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. Muramaki M; So A; Hayashi N; Sowery R; Miyake H; Fujisawa M; Gleave ME BJU Int; 2009 Feb; 103(3):384-90. PubMed ID: 19007378 [TBL] [Abstract][Full Text] [Related]
70. ATM regulates insulin-like growth factor 1-secretory clusterin (IGF-1-sCLU) expression that protects cells against senescence. Luo X; Suzuki M; Ghandhi SA; Amundson SA; Boothman DA PLoS One; 2014; 9(6):e99983. PubMed ID: 24937130 [TBL] [Abstract][Full Text] [Related]
71. Clusterin and chemoresistance. Djeu JY; Wei S Adv Cancer Res; 2009; 105():77-92. PubMed ID: 19879424 [TBL] [Abstract][Full Text] [Related]
72. Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth. Yao M; Sai W; Zheng W; Wang L; Dong Z; Yao D Curr Med Chem; 2020; 27(20):3290-3301. PubMed ID: 31232234 [TBL] [Abstract][Full Text] [Related]
73. Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Trougakos IP; Lourda M; Antonelou MH; Kletsas D; Gorgoulis VG; Papassideri IS; Zou Y; Margaritis LH; Boothman DA; Gonos ES Clin Cancer Res; 2009 Jan; 15(1):48-59. PubMed ID: 19118032 [TBL] [Abstract][Full Text] [Related]
74. Low dose IR-induced IGF-1-sCLU expression: a p53-repressed expression cascade that interferes with TGFβ1 signaling to confer a pro-survival bystander effect. Klokov D; Leskov K; Araki S; Zou Y; Goetz EM; Luo X; Willson D; Boothman DA Oncogene; 2013 Jan; 32(4):479-90. PubMed ID: 22391565 [TBL] [Abstract][Full Text] [Related]
75. A candidate single nucleotide polymorphism in the 3' untranslated region (rs17878624) of survivin gene for NSCLC. Aynaci E; Coskunpinar E; Yildiz P Cell Mol Biol (Noisy-le-grand); 2018 Mar; 64(4):119-122. PubMed ID: 29631694 [TBL] [Abstract][Full Text] [Related]
76. The chaperone activity of clusterin is dependent on glycosylation and redox environment. Rohne P; Prochnow H; Wolf S; Renner B; Koch-Brandt C Cell Physiol Biochem; 2014; 34(5):1626-39. PubMed ID: 25402950 [TBL] [Abstract][Full Text] [Related]
77. Novel nucleolar localization of clusterin and its associated functions in human oral cancers: An in vitro and in silico analysis. Kadam R; Harish M; Dalvi K; Teni T Cell Biochem Funct; 2021 Apr; 39(3):380-391. PubMed ID: 33155695 [TBL] [Abstract][Full Text] [Related]
78. Novel marine and microbial natural product inhibitors of vacuolar ATPase. Beutler JA; McKee TC Curr Med Chem; 2003 May; 10(9):787-96. PubMed ID: 12678782 [TBL] [Abstract][Full Text] [Related]
79. Transcriptomes of Clusterin- and S100B-transfected neuronal cells elucidate protective mechanisms against hypoxia and oxidative stress in the hooded seal (Cystophora cristata) brain. Martens GA; Geßner C; Osterhof C; Hankeln T; Burmester T BMC Neurosci; 2022 Oct; 23(1):59. PubMed ID: 36243678 [TBL] [Abstract][Full Text] [Related]
80. Vacuolar Proton-Translocating ATPase May Take Part in the Drug Resistance Phenotype of Glioma Stem Cells. Giambra M; Di Cristofori A; Raimondo F; Rigolio R; Conconi D; Chiarello G; Tabano SM; Antolini L; Nicolini G; Bua M; Ferlito D; Carrabba G; Giussani CG; Lavitrano M; Bentivegna A Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473989 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]